WallStSmart

Merck & Company Inc (MRK)vsPolyrizon Ltd. Ordinary Shares (PLRZ)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 53/100 (C-).

MRK

Buy

53

out of 100

Grade: C-

Growth: 3.3Profit: 8.5Value: 2.7Quality: 4.8
Piotroski: 2/9

PLRZ

Avoid

23

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 7.8
Piotroski: 4/9Altman Z: 7.67
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-15.7%)

Margin of Safety

-15.7%

Fair Value

$97.76

Current Price

$113.56

$15.80 premium

UndervaluedFair: $97.76Overvalued

Intrinsic value data unavailable for PLRZ.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK4 strengths · Avg: 9.5/10
Market CapQuality
$277.02B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
36.9%10/10

Every $100 of equity generates 37 in profit

Operating MarginProfitability
38.1%10/10

Strong operational efficiency at 38.1%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

PLRZ2 strengths · Avg: 10.0/10
Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Altman Z-ScoreHealth
7.6710/10

Safe zone — low bankruptcy risk

Areas to Watch

MRK4 concerns · Avg: 3.3/10
P/E RatioValuation
31.5x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
3.432/10

Expensive relative to growth rate

PLRZ4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$26.83M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin.

Bull Case : PLRZ

The strongest argument for PLRZ centers on Price/Book, Altman Z-Score.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Bear Case : PLRZ

The primary concerns for PLRZ are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (53/100 vs 23/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Polyrizon Ltd. Ordinary Shares

HEALTHCARE · BIOTECHNOLOGY · USA

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company is headquartered in Ra'anana, Israel.

Visit Website →

Want to dig deeper into these stocks?